Chinese Journal of Clinical Medicine 2025;32(1):140-144
doi:10.12025/j.issn.1008-6358.2025.20240434
Dual immune checkpoint inhibitors combined with anlotinib in the treatment of alveolar soft part sarcoma: a case report
Xinghua FANG 1 ; Wei LI 2 ; Yuhong ZHOU 2
Affiliations
Keywords
alveolar soft part sarcoma; immune checkpoint inhibitor; vascular inhibitor
Country
China
Language
Chinese
Abstract
Clinical data of a patient with alveolar soft part sarcoma (ASPS) treated at Zhongshan Hospital, Fudan University were retrospectively analyzed. The patient was initially diagnosed with abdominal ASPS with multiple lung metastases. After 6 weeks of treatment with nivolumab and ipilimumab, the patient achieved stable disease (SD). In the 7th week, the treatment was changed to a combination of nivolumab (30 mg, d1, q3w), anlotinib (8 mg, d1-14, q3w) and ipilimumab (50 mg, d1, q6w). The patient remained SD at the 12th week. The patient then underwent iliac artery embolization and intensity-modulated radiation therapy for the lesion in the psoas major muscle, while continuing the combination treatment. By the 24th week, the evaluation showed partial remission (PR) of both primary tumor and lung metastases. The patient experienced mild adverse reactions during treatment.
备案号: 11010502037788, 京ICP备10218182号-8)